Study on GJC2: Potential Drug Target and Biomarker for Various Diseases

Target Name: GJC2

NCBI ID: G57165

GJC2

Study on GJC2: Potential Drug Target and Biomarker for Various Diseases

GJC2 (LMPH1C), a protein located in the cell membrane of various cell types, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

GJC2 is a transmembrane protein that plays a crucial role in the regulation of cell signaling pathways. It is composed of two major domains: an extracellular domain responsible for its cell membrane localization and an intracellular domain that contains various enzymes involved in signaling pathways. The domain of GJC2 contains two key enzymes, GJC2-ALC (GJC2 activity-regulating enzyme) and GJC2-COM (GJC2 cytoplasmic domain interacting with matrix), which are involved in the regulation of intracellular signaling pathways.

GJC2 has been shown to play a significant role in various cellular processes, including cell signaling, cell adhesion, and cell survival. It has been shown to regulate the activity of many signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway , and the NF-kappa-B pathway. GJC2 has also been shown to interact with many different signaling molecules, including TGF-β, PDGF, and NF-kappa-B.

GJC2 has been linked to the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, GJC2 has been shown to be involved in the development of neurobladder cancer (GJC2-positive). Additionally, GJC2 has been shown to be involved in the development and progression of Alzheimer's disease, and may be a potential drug target for this disease.

GJC2 has also been shown to be involved in the regulation of cellular Immune Response (CMR), which is the process by which the immune system defends the body against foreign invasion, and is crucial for maintaining the health and wellbeing of the body. Dysregulation of CMR has been implicated in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, GJC2 may be a potential drug target for these diseases as well.

GJC2 is also a good candidate for a biomarker for many diseases, as its expression and function can be easily measured and correlated with disease progression. For example, GJC2 has been shown to be involved in the regulation of many diseases, including cancer, neurodegenerative diseases , and autoimmune disorders. Therefore, its levels or expression may be used as a biomarker for these diseases.

In conclusion, GJC2 is a protein with unique structure and function that has been shown to play a significant role in the regulation of cell signaling pathways and the development and progression of many diseases. Its potential as a drug target and biomarker make it an attractive target for further research and development. Further studies are needed to fully understand its role in these diseases and to develop new treatments.

Protein Name: Gap Junction Protein Gamma 2

Functions: One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. May play a role in myelination in central and peripheral nervous systems

The "GJC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GJC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets